Journal of Experimental & Clinical Cancer Research

Celebrating the 10th anniversary partnership with BMC

2018 marks the 10^th anniversary of the partnership between the Journal of Experimental & Clinical Cancer Research and BMC.

Over the past decade, the journal has established itself among some of the top Oncology titles in Journal Citation Reports. Click here to look back at some of the journal’s milestone achievements and best content from the past 10 years.

Featured Article: The perfect personalized cancer therapy: cancer vaccines against neoantigens

Personalized cancer therapy is an emerging field in oncology research since the premise of being able to specifically target a causative mutation of a tumor, whilst reducing the side-effects of normal tissue, enables this type of approach to be uniquely tailored to each patient, to help maximize the effectiveness that the therapy will have. Targeting tumor neoantigens are considered an ideal target in personalized cancer therapy.

In this review, L. Aurisicchio et al. give an overview on immune recognition of tumor cells and discuss the evidence regarding mutation-derived neoantigen cancer vaccines.

Click here to access the full article.

Click here to access all of the reviews published to date in Journal of Experimental & Clinical Cancer Research.

Aims and scope

Journal of Experimental & Clinical Cancer Research is an online peer-reviewed journal that provides a high-quality forum for all aspects of basic, clinical and translational work in oncology.

Please click here to read more.

Content type: Research
| 21 September 2018

The LAT1 inhibitor JPH203 reduces growth of thyroid carcinoma in a fully immunocompetent mouse model

Authors: Pascal Häfliger, Julien Graff, Matthias Rubin, Amandine Stooss, Matthias S. Dettmer, Karl-Heinz Altmann, Jürg Gertsch and Roch-Philippe Charles
Content type: Research
| 21 September 2018

Effects of repurposed drug candidates nitroxoline and nelfinavir as single agents or in combination with erlotinib in pancreatic cancer cells

Authors: Serena Veschi, Laura De Lellis, Rosalba Florio, Paola Lanuti, Alberto Massucci, Nicola Tinari, Michele De Tursi, Pierluigi di Sebastiano, Marco Marchisio, Clara Natoli and Alessandro Cama
Content type: Research
| 21 September 2018

miR-203 inhibits ovarian tumor metastasis by targeting BIRC5 and attenuating the TGFβ pathway

Authors: Baojin Wang, Xia Li, Guannan Zhao, Huan Yan, Peixin Dong, Hidemichi Watari, Michelle Sims, Wei Li, Lawrence M Pfeffer, Yuqi Guo and Junming Yue
Content type: Research
| 20 September 2018

Integrated genomic analyses in PDX model reveal a cyclin-dependent kinase inhibitor Palbociclib as a novel candidate drug for nasopharyngeal carcinoma

Authors: Cheng-Lung Hsu, Kar-Wai Lui, Lang-Ming Chi, Yung-Chia Kuo, Yin-Kai Chao, Chun-Nan Yeh, Li-Yu Lee, Yenlin Huang, Tung-Liang Lin, Mei-Yuan Huang, Yi-Ru Lai, Yuan-Ming Yeh, Hsien-Chi Fan, An-Chi Lin, Yen-Jung Lu, Chia-Hsun Hsieh…
Content type: Research
| 19 September 2018

The effects of ultrasound exposure on P-glycoprotein-mediated multidrug resistance in vitro and in vivo

Authors: Chixiong Huang, Senlin Huang, Hairui Li, Xinzhong Li, Bing Li, Lintao Zhong, Junfeng Wang, Meishen Zou, Xiang He, Hao Zheng, Xiaoyun Si, Wangjun Liao, Yulin Liao, Li Yang and Jianping Bin

Most recent articles RSS

View all articles

Content type: Review
| 26 September 2011

Apoptosis in cancer: from pathogenesis to treatment

Authors: Rebecca SY Wong
Content type: Review
| 6 October 2015

Metabolic reprogramming: the emerging concept and associated therapeutic strategies

Authors: Go J. Yoshida
Content type: Research
| 3 February 2016

HIF-2α promotes epithelial-mesenchymal transition through regulating Twist2 binding to the promoter of E-cadherin in pancreatic cancer

Authors: Jian Yang, Xu Zhang, Yi Zhang, Dongming Zhu, Lifeng Zhang, Ye Li, Yanbo Zhu, Dechun Li and Jian Zhou
Content type: Research
| 14 September 2009

Characterization of human breast cancer epithelial cells (HBCEC) derived from long term cultured biopsies

Authors: Ralf Hass and Catharina Bertram
Content type: Research article
| 5 February 2015

Elevated kinesin family member 26B is a prognostic biomarker and a potential therapeutic target for colorectal cancer

Authors: Jingtao Wang, Feifei Cui, Xiao Wang, Yingming Xue, Jian Chen, Yang Yu, Huijun Lu, Meng Zhang, Huamei Tang and Zhihai Peng

Most accessed articles RSS

View all articles

Meeting reports now accepted

Journal of Experimental & Clinical Cancer Research now welcomes the submission of Meeting reports to help showcase novel developments presented at meetings and conferences.

Please click here for more information on the article types accepted by Journal of Experimental & Clinical Cancer Research.

Editor-in-Chief

Mauro Castelli, Regina Elena National Cancer Institute, Italy

If you would like to contact Journal of Experimental & Clinical Cancer Research, please send an email to:

jeccreditorial@gmail.com

2017 Impact Factor

We are delighted to share with our readers that Journal of Experimental & Clinical Cancer Research has an Impact Factor of 6.217 and is currently ranked at 33 out of 222 (Q1) in the Oncology category of Journal Citation Reports (Clarivate Analytics, 2018).

We would like to extend our appreciation to all Editorial Board Members, authors and peer reviewers who have contributed to the journal and enabled this achievement.

Archival content

Journal of Experimental & Clinical Cancer Research has been publishing since 1982. Prior to publishing with BioMed Central from 2008, Journal of Experimental & Clinical Cancer Research was published in print. For enquiries about previous content, please contact us on:

jeccreditorial@gmail.com

Reviewer Acknowledgement

The editorial team of Journal of Experimental & Clinical Cancer Research would like to thank all of our reviewers who have contributed to the journal.

Click here to visit the Reviewer acknowledgements page.

Journal of Experimental & Clinical Cancer Research

Celebrating the 10th anniversary partnership with BMC

Featured Article: The perfect personalized cancer therapy: cancer vaccines against neoantigens

Aims and scope

Articles

The LAT1 inhibitor JPH203 reduces growth of thyroid carcinoma in a fully immunocompetent mouse model

Effects of repurposed drug candidates nitroxoline and nelfinavir as single agents or in combination with erlotinib in pancreatic cancer cells

miR-203 inhibits ovarian tumor metastasis by targeting BIRC5 and attenuating the TGFβ pathway

Integrated genomic analyses in PDX model reveal a cyclin-dependent kinase inhibitor Palbociclib as a novel candidate drug for nasopharyngeal carcinoma

The effects of ultrasound exposure on P-glycoprotein-mediated multidrug resistance in vitro and in vivo

Apoptosis in cancer: from pathogenesis to treatment

Metabolic reprogramming: the emerging concept and associated therapeutic strategies

HIF-2α promotes epithelial-mesenchymal transition through regulating Twist2 binding to the promoter of E-cadherin in pancreatic cancer

Characterization of human breast cancer epithelial cells (HBCEC) derived from long term cultured biopsies

Elevated kinesin family member 26B is a prognostic biomarker and a potential therapeutic target for colorectal cancer

Meeting reports now accepted

Editor-in-Chief

2017 Impact Factor

Archival content

Reviewer Acknowledgement

Follow

2017 Journal Metrics

Journal of Experimental & Clinical Cancer Research

Contact us